Stockreport

Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals, Ltd. - Class A  (KNSA) 
Last kiniksa pharmaceuticals, ltd. - class a earnings: 8/12 04:02 pm Check Earnings Report
PDF – ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth –– ARCALYST 2025 expected net product revenue raised to $6 [Read more]